GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Gross Margin %

Rosetta Genomics (Rosetta Genomics) Gross Margin % : 34.60% (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Rosetta Genomics's Gross Profit for the three months ended in Jun. 2017 was $0.30 Mil. Rosetta Genomics's Revenue for the three months ended in Jun. 2017 was $0.87 Mil. Therefore, Rosetta Genomics's Gross Margin % for the quarter that ended in Jun. 2017 was 34.60%.


The historical rank and industry rank for Rosetta Genomics's Gross Margin % or its related term are showing as below:


ROSGQ's Gross Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 45.55
* Ranked among companies with meaningful Gross Margin % only.

Rosetta Genomics had a gross margin of 34.60% for the quarter that ended in Jun. 2017 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Rosetta Genomics was 0.00% per year.


Rosetta Genomics Gross Margin % Historical Data

The historical data trend for Rosetta Genomics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Gross Margin % Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.36 -75.06 1.28 24.14 19.44

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.30 -22.77 18.64 0.84 34.60

Competitive Comparison of Rosetta Genomics's Gross Margin %

For the Diagnostics & Research subindustry, Rosetta Genomics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Gross Margin % falls into.



Rosetta Genomics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Rosetta Genomics's Gross Margin for the fiscal year that ended in Dec. 2016 is calculated as

Gross Margin % (A: Dec. 2016 )=Gross Profit (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=1.8 / 9.234
=(Revenue - Cost of Goods Sold) / Revenue
=(9.234 - 7.439) / 9.234
=19.44 %

Rosetta Genomics's Gross Margin for the quarter that ended in Jun. 2017 is calculated as


Gross Margin % (Q: Jun. 2017 )=Gross Profit (Q: Jun. 2017 ) / Revenue (Q: Jun. 2017 )
=0.3 / 0.87
=(Revenue - Cost of Goods Sold) / Revenue
=(0.87 - 0.569) / 0.87
=34.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Rosetta Genomics  (OTCPK:ROSGQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Rosetta Genomics had a gross margin of 34.60% for the quarter that ended in Jun. 2017 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Rosetta Genomics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458